Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $0.10, $0.30 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $9.5 billion versus the consensus estimate of $8.97 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2023 EPS of $6.50-$6.70, versus the consensus of $6.72.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.